Düsseldorf, March 9, 2022
DermaTools Biotech GmbH and its financial investor CytoTools AG conclude settlement agreement after months of negotiations
Rellermeyer represents the managing shareholders of DermaTools Biotech GmbH and former board members of CytoTools AG
With a settlement agreement dated 08.03.2022, DermaTools Biotech GmbH and its financial investor CytoTools AG have settled disputes which had arisen among the shareholders of DermaTools Biotech GmbH and with former members of the Management Board and Supervisory Board of CytoTools AG. The settlement agreement clears the way for the successful development of DermaPro, the product of DermaTools Biotech GmbH, and for a capital increase of the listed financial investor CytoTools AG, which was resolved in December 2021.
Rellermeyer thus continues its success in reaching settlements in complex shareholder disputes.
Dr. Klaus Rellermeyer, Dr. Stefan Gröblinghoff, Johannes Song